Mechanisms of skeletal muscle degradation and its therapy in cancer cachexia

Histology and Histopathology

Volumn 22, Issue 7-9, 2007, Pages 805-814

  Melstrom, L G ^a   Melstrom Jr , K A ^b   Ding, X Z ^a   Adrian, Thomas E ^a,c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^c UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

Author keywords

Cancer cachexia; Skeletal muscle degradation

Indexed keywords

21 EPOXYRESIBUFOGENIN 3 ACETATE; ANTINEOPLASTIC AGENT; ARGININE; CILIARY NEUROTROPHIC FACTOR; CNTO 328; CORTICOSTEROID; CYTOKINE; CYTOKINE RECEPTOR ANTAGONIST; GAMMA INTERFERON; GAMMA INTERFERON ANTIBODY; ICOSAPENTAENOIC ACID; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; MEGESTROL ACETATE; MINERAL; MONOCLONAL ANTIBODY; OMEGA 3 FATTY ACID; PENTOXIFYLLINE; PLACEBO; PROTEASOME; PROTEINASE; RECOMBINANT INTERLEUKIN 1BETA; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; UBIQUITIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITAMIN; APPETITE STIMULANT; MUSCLE PROTEIN; PEPTIDE HYDROLASE;

ADVANCED CANCER; CACHEXIA; CANCER PATIENT; CATABOLISM; CHRONIC DISEASE; CLINICAL TRIAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; CYTOKINE PRODUCTION; CYTOSOL; DELIRIUM; DEPRESSION; DIET SUPPLEMENTATION; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ENTERIC FEEDING; ENZYME ACTIVITY; GASTROINTESTINAL OBSTRUCTION; HUMAN; IMMUNE DEFICIENCY; LOW DRUG DOSE; LUNG ADENOCARCINOMA; LYSOSOME; MELANOMA; META ANALYSIS; MORBIDITY; MORTALITY; MUSCLE ATROPHY; MUSCLE MASS; NONHUMAN; PAIN; PANCREAS CANCER; PARENTERAL NUTRITION; PATHOGENESIS; PROSTATE CANCER; PROSTATE SURGERY; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN TARGETING; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SARCOMA; SIDE EFFECT; SKELETAL MUSCLE; STARVATION; SYSTEMATIC REVIEW; WEAKNESS; WEIGHT REDUCTION; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; NUTRITIONAL SUPPORT; PANCREAS TUMOR;

ADRENAL CORTEX HORMONES; ANIMALS; APPETITE STIMULANTS; CACHEXIA; CYTOKINES; HUMANS; LYSOSOMES; MEGESTROL ACETATE; MUSCLE PROTEINS; MUSCLE, SKELETAL; NUTRITIONAL SUPPORT; PANCREATIC NEOPLASMS; PEPTIDE HYDROLASES; PROTEASOME ENDOPEPTIDASE COMPLEX; UBIQUITIN;

EID: 34248584713     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (96)

1. Acharyya S., Ladner K., Nelsen L., Damrauer J., Reiser P., Swoap S. and Guttridge D. (2004). Cancer cachexia is regulated by selective targeting of skeletal muscle gene products. J. Clin. Invest. 114, 370-378.
2. Argiles J.M., Meijsing S.H., Pallares-Trujillo J., Guirao X. and Lopez-Soriano F.J. (2001). Cancer cachexia: A therapeutic approach. Med. Res. Rev. 21, 83-101.
3. Argiles J., Busquets S. and Lopez-Soriano F. (2003). Cytokines in the pathogenesis of cancer cachexia. Curr Opin. Clin. Nutr. Metab. Care 6, 401-406.
4. Baracos V., Rodeman H.P., Dinarello C.A. and Goldberg A.L. (1983). Stimulation of muscle protein degradation and prostaglandin E2 release by leukocyte pyrogen (interleukin-1). N. Engl. J. Med. 308, 553-555.
5. Baracos V.E., DeVivo C., Hoyle D.H. and Goldberg A.L. (1995). Activation of the ATP-ubiquitin-proteasome pathwayin skeletal muscle of cachectic rats bearing a hepatoma. Endocrinol. Metab. 31, E996-E1006.
6. Beek S.A., Smith K.L. and Tisdale M.J. (1991). Anticachectic and antitumour effect of eicosapentaenoic acid and its effect on protein turnover. Cancer Res. 51, 6089-6093.
7. Beutler B. and Cerami A. (1988). Tumor necrosis, cachexia, shock, and inflammation: a common mediator. Annu. Rev. Biochem. 57, 505-518.
8. Brennan M.F., Pisters P.W.T., Posner M., Quesada O. and Shike M. (1994). A prospective randomized trial of total parenteral nutrition after major pancreatic resection for malignancy. Ann. Surg. 220, 436-441.
9. Bruera E., Macmillian K., Kuehn N., Hanson J. and MacDonald R.N. (1990). A controlled trial of megestrol acetate on appetite, caloric intake, nutritional status and other symptoms in patients with advanced cancer. Cancer 66, 1279-1282.
10. Bruera E., Roca E., Cedaro L., Carraro S. and Chacon R. (1985). Action of oral methylprednisolone in terminal cancer patients: a prospective randomized doubl-blind study. Cancer Treat Rep. 69, 751-754.
11. Cabal-Manzano R., Bhargava P., Torres-Duarte A., Marshall J., Bhargava P. and Wainer I.W. (2001). Proteolysis-inducing factor is expressed in tumors of patients with gastrointestinal cancers and correlates with weight loss. Br. J. Cancer 84, 1599-1601.
12. Cahlin C., Korner A., Axelsson H., Wang W., Lundholm K. and Svanberg E. (2000). Experimental cancer cachexia: The role of host-derived cytokines; interleukin (IL)-6, IL-12, interferon-gamma, and tumor necrosis factor alpha evaluated in gene knockout, tumor-bearing mice on C57 B1 background and eicosanoid-dependent cachexia. Cancer Res. 60, 5499-5493.
13. Cariuk P., Lorite M.J., Todorov P.T., Field W.N., Wigmore S.J. and Tisdale M.J. (1997). Induction of cachexia in mice by a product isolated from the urine of cachectic cancer patients. Br. J. Cancer 76, 606-613.
14. Clark R.H., Feleke G., Din M., Yasmin T., Singh G., Khan F.A. and Rathmacher J.A. (2000). Nutritional treatment of acquired immunodeficiency virus-associated wasting using beta-methylbutyrate, glutamine, and arginine; a randomized, doubleblind, placebo-controlled study. J. Parenter. Enteral Nutr. 24, 133-139.
15. Costelli P., Carbo N., Tessitore L., Bagby G.J., Lopez-Soriano F.J., Argiles J.M. and Baccino F.M. (1993). Tumor necrosis factor-α mediates changes in tissue protein turnover in a rat cancer cachexia model. J. Clin. Invest., 92, 2783-2789.
16. Costelli P.L.M., Carbo N., Garcia-Martinez C., Lopez-Soriano F.J. and Argiles J.M. (1995). Interleukin-1 receptor antagonist (IL-1ra) is unable to reverse cachexia in rats bearing an ascites hepatoma (Yoshida AH-130). Cancer Lett, 95, 33-38.
17. Daly J.M., Lieberman M.D., Goldfine J., Shou J., Weintraub F., Rosato E.F. and Lavin P. (1992). Enteral nutrition with supplemental arginine, RNA, and omega-3 fatty acids in patients after operation: immunologic, metabolic, and clinical outcome. Surgery 112, 56-67.
18. Daly J.M., Weintraub F.N., Shou J., Rosato E.F. and Lucia M. (1995). Enteral nutrition during multimodality therapy in upper gastrointestinal cancer patients. Ann. Surg. 221, 327-338.
19. Detsky A.S., Baker J.P., O'Rourke K. and Goel V. (1987). Perioperative parenteral nutrition: a meta-analysis. Ann. Intern. Med. 107, 195-203.
20. Emilie D., Wijdenes J., Gisselbrecht C., Jarrousse B., Billaud E., Blay J.Y., Gabarre J., Gaillard J.P., Brochier J. and Raphael M. (1994). Administration of an interleukin-6 monoclonal antibody to patients with acquired immunodeficiency syndrome and lymphoma: effect on lymphoma growth and on B clinical symptoms. Blood 84, 2472-2479
21. Enomoto A., Rho M.-C., Fukami A., Hiraku O., Komiyama K. and Hayashi M. (2004). Suppression of cancer cachexia by 20S,21-epoxy-resibufogenin-3-acetate-a novel nonpeptide IL-6 receptor antagonist. Biochem and Biophys Res Comm, 323, 1096-1102.
22. Evans R.D., Argiles M. and Williamson D.H. (1989). Metabolic effects of tumour necrosis factor-α (cachectin) and interieukin-1. Clin. Sci. 77, 357-364.
23. Falconer J.S., Fearon K.C.H., Plester C.E., Ross J.A. and Carter D.C. (1994). Cytokines, the acute-phase response, and resting energy expenditure in cachectic patients with pancreatic cancer. Ann. Surg, 219, 323-324.
24. Fearon K.C.H. (1992). The mechanisms and treatment of weight loss in cancer. Proc. Nutr. Soc. 51, 251-265.
25. Fearon K.C.H., von Meyenfeldt M.F., Moses A.G.W., van Geenen R., Roy A., Gouma D.J., Giacosa A., Van Gossum A., Bauer J., Barber, M.D., Aaronson N.K., Voss A.C. and Tisdale M.J. (2001). Effect of a protein and energy dense n-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial. Gut 52, 1479-1486.
26. Feliu J., Gonzalez-Baron M., Berrocal A., Artral A., Ordonez A., Garrido P., Zamora P., Garcia de Paredes M.L. and Montero J.M. (1992). Usefulness of megestrol acetate in cancer cachexia and anorexia. Am. J. Clin. Oncol. 15, 436-440.
27. Femia R.A. and Goyette R.E. (2005). The science of megestrol acetate delivery: potential to improve outcomes in cachexia. Biol. Drugs 19, 179-87.
28. Fong Y., Moldawer L.L., Morano M., Wei H., Barber A., Manogue K., Tracey K.H., Kuo G., Fischman D.A., Cerami A. and Lowery S.F. (1989). Cachectin/ TNF or IL-1 alpha induces cachexia with redistribution of body proteins. Am. J. Physiol. 256, R659-665.
29. Fujita J., Tsujinaka T., Yano M., Ebisui C., Saito H., Katsume A., Akamatsu K., Ohsugi Y., Shiozaki H. and Monden M. (1996). Anti-interleukin-6 receptor antibody prevents muscle atrophy in colon-26 adenocarcinoma-bearing mice with modulatin of lysosomal and ATP-ubiquitin-dependent proteolytic pathways. Int. J. Cancer 68, 637-643.
30. 2+ or muscle injury does not involve a lysosoma mechanism. Biochem. J. 237, 859-864.
31. Garcia-Martinez C., Llovera M., Agell N., Lopez-Soriano F.J. and Argiles J.M. (1994). Ubiquitin gene expression in skeletal muscle is increased by tumor necrosis factor-α. Biochem. Biophys. Res. Commun. 201, 682-686.
32. Garcia-Martinez, C., Lopez-Soriano, F.J. and Argiles, J.M. (1993). Acute treatment with tumour necrosis factor-alpha induces changes in protein metabolism in rat skeletal muscle. Mol. Cell Biochem. 125, 11-18.
33. Gold E.B. and Goldin S.B. (1998). Epidemiology of and risk factors for pancreatic cancer. Surg. Oncol. Clin. North. Am. 7, 67-91.
34. 2 production in rat skeletal muscle in fever is signaled by a macrophage product distinct from interleukin-1 or other known monokines. J. Clin. Invest. 81, 1378-1383.
35. Goldberg R.M., Loprinzi C.L., Mailliard J.A., O'Fallon J.R., Krook J.E., Ghosh C., Hesteroff R.D., Chong S.F., Reuter N.F. and Shanahan T.G. (1995). Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double-blind, placebo-controlled trial. J. Clin. Oncol. 13, 2856-2859.
36. Goll D.E., Thompson V.F., Taylor R.G. and Christiansen J.A. (1992). Role of the calpain system in muscle growth. Biochimie 74, 225-237.
37. Goodman M.N. (1994). Interleukin-6 induces skeletal muscle protein breakdown in rats. Proc. Soc. Exp. Biol. Med. 205, 182-185.
38. Gordon J.N., Trebbel T.M., Ellis R.D., Duncan H.D., Johns T. and Goggin P.M. (2005). Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial. Gut 54, 540-545.
39. Gronostajski R.M., Goldberg A.L. and Pardee A.B. (1984). The role of increased proteolysis in the atrophy and arrest of proliferation in serum-deprived fibroblasts. J. Cell. Physiol. 121, 189-198.
40. Henderson J.T., Mullen G.J. and Roder J.C. (1996). Physiological effects of CNTF-induced wasting, Cytokine 8, 784-793
41. Hesli M.J., Latkany L., Leung D., Brooks A.D., Hochwald S.N., Pisters P.W.T., Shike M. and Brennan M.F. (1997). A prospective, randomized trial of early enteral feeding after resection of upper gastrointestinal malignancy. Ann. Surg. 4, 567-580.
42. Heymsfield S.B. and McManus C.B. (1985). Tissue components of weight loss in cancer patients. Cancer 55, 2238-2242.
43. Heys S.D., Walker L.G., Smith I. and Eremin O. (1999). Enteral nutritional supplementation with key nutrients in patients with critical illness and cancer: a meta-analysis of randomized controlled clinical trials. Ann. Surg. 229, 467-477.
44. Jatoi A., Foster N., Wieland B., Murphy B., Nikcevich D., LePlant B., Palcic M.M. and Baracos V. (2006). The proteolysis-inducing factor: In search of its clinical relevance in patients with metastatic gastric/ esophageal cancer. Dis. Esophagus 19, 241-247.
45. Kwak K., Xhou X., Solomon V., Baracos V., Davis J., Bannon A., Boyle W., Lacey D. and Han H. (2004). Regulation of protein catabolism by muscle-specific and cytokine-inducible ubiquitin ligase E3α-II during Cancer Cachexia. Cancer Res. 64, 8193-8198.
46. Lecker S.H., Solomon V., Mitch W.E. and Goldberg A.L. (1999). Muscle protein breakdown and the critical role of the ubiquitin-proteasome pathway in normal and disease states. J. Nutr. 129, 227S-237S.
47. Li Y.-P., Schwartz R.J., Waddell I.D., Holloway B.R. and Reid M.B. (1998). Skeletal muscle myocytes undergo protein loss and reactive oxygen-mediated NF-κB activation in response to tumor necrosis factor a. FASEB J. 12, 871-880.
48. Ling P.K., Istfan N., Blackburn G.L. and Bistrian B.R. (1991). Effects of interleukin 1-β (IL-1) and combination of IL-1 and tumor necrosis factor on tumor growth and protein metabolism. J. Nutr. Biochem. 2, 553-559.
49. Llovera M., Carbo N., Lopez-Soriano J., Garcia-Martinez C., Busquets S., Alvarez B., Agell N., Costelli P., Lopez-Soriano F.J., Celada A. and Argiles J.M. (1998). Different cytokines modulate ubiquitin gene expression in rat skeletal muscle. Cancer Lett. 133, 83-87.
50. Llovera M., Garcia-Martinez C., Agell N., Lopez-Soriano F.J. and Argiles J.M. (1997). TNF can directly induce the expression of ubiquitin-dependent proteolytic system in rat soleus M muscles. Biochem. Biophys. Res. Comm. 230, 238-241.
51. Loprinzi C.L., Ellison N.M., Schaid D.J., Krook J.E., Athman L.M., Dose A.M., Mailliard J.A., Johnson P.S., Ebbert L.P. and Geeraerts L.H. (1990). Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. J. Natl. Cancer Inst. 82, 1127-32.
52. Lorite M.J., Cariuk P. and Tisdale M.J. (1997). Induction of muscle protein degradation by a tumour factor. Br. J. Cancer 76, 1035-1040.
53. Lorite M.J., Smith H.J., Arnold J.A., Morris A., Thompson M.G. and Tisdale M.J. (2001). Activation of ATP-ubiquitin-dependent proteolysis in skeletal muscle in vivo and murine myoblasts in vitro by a proteolysis-inducing factor. Br. J. Cancer 85, 297-302.
54. Lowell B.B., Ruderman N.B. and Goodman M.N. (1986). Evidence that lysosomes are not involved in the degradation of myofibrillar proteins in rat skeletal muscle. Biochem. J. 234, 237-240.
55. Maltoni M., Fabbri L., Nanni O., Scarpi E., Pezzi L., Flamini E., Riccobon A., Derni S., Pallotti G. and Amadori D. (1997). Serum levels of tumour necrosis factor alpha and other cytokines do not correlate with weight loss and anorexia in cancer patients. Support Care Cancer 5, 130-135.
56. Matthys P. and Billiau A. (1997). Cytokines and cachexia. Nutrition 13, 763-770.
57. Matthys P.D.R., Proost P., Van Damme J., Heremans H., Sobis H. and Billiau A. (1991). Severe cachexia in mice inoculated with interferon-gamma-producing tumor cells. Int. J. Cancer 49, 77-82.
58. May P.E., Barber A., D'Olimpio J.T., Hourihane A. and Abumrad N.N. (2002). Reversal of cancer-related wasting using oral supplementation with a combination of beta-hydroxy-beta-methylbutyrate, arginine and glutamine. Am. J. Surg. 183, 471-479.
59. Mellgren R.L. (1987). Calcium-dependent proteases: an enzyme system acive at cellular membranes? FASEB J. 1, 110-115.
60. Mitch W.E. and Goldberg A.L. (1996). Mechanism of muscle wasting the role of the ubiquitin-proteasome pathway. New Engl. J. Med. 335, 1897-1905.
61. Mitch W.E., Medina R., Grieber S., May R.C., England B.K., Price S.R., Baily J.L. and Goldberg A.L. (1994). Metabolic acidosis stimulates muscle protein degradation by activating the adenosine triphosphate-dependent pathway involving ubiquitin and proteasomes. J. Clin. Invest. 93, 2127-2133.
62. Moertel C.G., Schutt A.J., Reltemeier R.J. and Hahn R.G. (1974). Corticosteroid therapy of preterminal gastrointestinal cancer. Cancer 33, 1607-1609.
63. Moldawer L.L. and Copeland E.M. (1997). Proinflammatory cytokines, nutritional support, and the cachexia syndrome: interaction and therapeutic options. Cancer 79, 1828-1839.
64. Moley J.F., Aamodt R., Rumble W., Kaye W. and Norton J.A. (1987). Body cell mass in cancer bearing and anorexia patients. JPEN 11, 219-222.
65. Monitto C.L., Dong S.M., Jen J. and Sidransk D. (2004). Characterization of a human homologue of proteolysis-inducing factor and its role in cancer cachexia. Clin. Cancer Res. 10, 5862-5869.
66. Moreira A.L., Sampaio E.P., Zmuidzinas A., Frindt P., Smith K.A. and Kaplan G. (1993). Thalidomide exerts its inhibitory action on tumor necrosis factor-α by enhancing mRNA degradation. J. Exp. Med. 177, 1675-80.
67. Moses A.W.G., Slater C., Preston T., Barber M.D. and Fearon K.C.H. (2004). Reduced total energy expenditure and physical activity in cachectic patients with pancreatic cancer can be modulated by an energy and protein dense oral supplement enriched with n-3 fatty acids. Brit. J. Cancer, 90, 996-1002.
68. 2+-dependent proteae (calpaine) and its high-molecular-weight endogenous inhibitor (calpastatin). Adv. Enzyme Regul. 19, 407-424.
69. Oliff A., Defeo-Jones D.M., Boyer D.M., Kiefer D., Vuocolo G., Wolfe A. and Socher S.H. (1987). Tumors secreting human TNF/cachectin induce cachexia in mice. Cell 50, 555-563.
70. Palesty J. and Dudrick S. (2003). What we have learned about cachexia in gastrointestinal cancer. Dig. Dis. 21, 198-213.
71. Popiela T., Lucchi R. and Giongo F. (1989). Methylprednisolone as a palliative therapy for female terminal cancer patients. The Methylprednisolone Female Preterminal Cancer Study Group. Eur. J. Cancer Clin. Oncol. 25, 1823-1829.
72. Ryan D.P. and Grossbard M.L. (1998). Pancreatic cancer: local success and distant failure. Oncologist 3, 178-188.
73. Schubert U., Anton L.C., Gibbs J., Norbury C.C., Yewdell J.W. and Bennink J.R. (2000). Rapid degradation of a large fraction of newly synthesized proteins by proteasomes. Nature 404, 770-774.
74. Sherry B.A., Gelin J., Fong Y., Marano M., Wei H., Cerami A., Lowry S.F., Lundholm K.G. and Moldawer L.L. (1989). Anticachectin tumor necrosis factor-alpha antibodies attenuate development of cachexia in tumor models. FSEB J. 3, 1956-1962.
75. Siampaio E.P., Sarno EX, Galilly R., Cohn Z.A. and Kaplan G. (1991). Thalidomide selectively inhibits tumor necrosis factor-α production in stimulated human monocytes. J. Exp. Med. 173, 699-703.
76. Society A.C. (2006). What are the key statistics of the cancer of the pancreas? Vol. 2006. ACS.
77. Splinter T.A. (1992). Cachexia and cancer: a clinician's view. Ann. Oncol. 3 (Suppl.), 25-27.
78. Starnes H.F., Warren R.S., Jeevanandam M., Gabrilove J.L., Larchian W., Oetten H.F. and Brennan M.F. (1988). Tumor necrosis factor and the acute metabolic response to tissue injury in man. J. Clin. Invest. 82, 1321-1325.
79. Strassman G., Fong M., Freter C.E., Windsor S., D'Alessandro F. and Nordan R.P. (1993a). Suramin interferes with interleukin-6 receptor binding in vitro and inhibits colon-26-mediated experimental cancer Cachexia In Vivo. J. Clin. Invest. 92, 2152-2159.
80. Strassman G.Y., Masui Y., Chizzonite R. and Fong M. (1993b). Mechanisms of experimental cancer cachexia. Local involvement of IL-1 colon-26 tumor. J. Immunol. 150, 2341-2345.
81. Tchekmedian N.S., Hickman M., Siau J., Greco A. and Aisner J. (1990). Treatment of cancer anorexia with megestrol acetate: impact on quality of life. Oncology 4, 185-92.
82. Tisdale M.J. (2002). Cachexia in cancer patients. Nat. Rev. Cancer 2, 862-871.
83. Tisdale M.J. (2005). The ubiquitin-proteasome pathway as a therapeutic target for muscle wasting. J. Support Oncol. 3, 209-217.
84. Todorov P., Cariuk P., McDevitt T., Coles B., Fearon K. and Tisdale M.J. (1996). Characterization of a cancer cachectic factor. Nature 379, 739-42.
85. Turrin N.P., Ilyin S.E., DAPlata-Salaman C.R.G., Ramos E.J.B., Laviano A., Das U.N., Inui A. and Meguid M.M. (2004). Interleukin-1β system in anorectic catabolic tumor-bearing rats. Curr. Opin. Clin. Nutr. Metab. Care 7, 419-426.
86. Uomo G., Gallucci F. and Rabitti P.G. (2006). Anorexia-cachexia syndrome in pancreatic cancer: Recent development in research and management. J. Pancreas 7, 157-162.
87. Vadell C., Segui M.A., Gimenez-Arnau J.M., Morales S., Cirera L., Bestit I., Batiste E., Blanco R., Jolis L., Boleda M. and Anton I. (1998). Anticachectic efficacy of megestrol acetate at different doses and versus placebo in patients with neoplastic cachexia. Am. J. Clin. Oncol. 21, 347-351.
88. Wang M.C. and Forsberg N.E. (2000). Effects of ciliary neurotrophic factor (CNTF) on protein turnover in cultured muscle cells. Cytokine 12, 41-48.
89. Watchorn T.M., Waddell I., Dowidar N. and Ross J.A. (2001). Proteolysis-inducing factor regulates hepatic gene expression via the transcription factors NF-kB and STAT3. FASEB J. 15, 562-564.
90. Waxman L. (1981). Calcium-activated proteases in mammalian tissues. Methods Enzymol. 80, 664-680.
91. Whitehouse A.S., Smith H.J., Drake J.L. and Tisdale M.J. (2001). Mechanism of Attenuation of Skeletal Muscle Protein Catabolism in Cancer Cachexia by Eicosapentaenoic Acid. Cancer Res. 61, 3604-3609.
92. Williams M.L., Torres-Duarte A., Brant L.J., Bhargava P., Marshall J. and Wainer I.W. (2004). The relationship between a urinary cachectic factor and weight loss in advanced cancer patients. Cancer Invest. 22, 866-870.
93. Willox J.C., Corr J., Shaw J., Richardson M., Calman K.C. and Drennan M. (1984). Prednisolone as an appetite stimulant in patients with cancer. Br. Med. J. (Clin. Res. Ed.), 288, 27.
94. Windsor S.A. and Hill G.L. (1988). Weight loss with physiologic impairment: a basic indicator of surgical risk. Ann. Surg., 207, 290-296.
95. Wing S.S. and Goldberg A.L. (1993). Glucocorticoids activate the ATP-ubiquitin dependent proteolytic system in skeletal muscle during fasting. Am. J. Physiol. 264, E668-E676.
96. Zaki M., Nemeth J. and Trikha M. (2004). CNTO 328, A monoclonal Antibody to IL-6, Inhibits Human Tumor-induced Cachexia in Nude Mice. Int. J. Cancer 111, 592-595.